Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
190.90
-1.96 (-1.02%)
Sep 23, 2026, 3:39 PM EDT - Market open
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$2,002,588
Market Cap
40.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,119 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
RVMD News
- 2 days ago - Revolution Medicines price target raised to $265 from $225 at BofA - TheFly
- 8 days ago - Revolution Medicines gets orphan designation for pancreatic cancer treatment - TheFly
- 8 days ago - Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA - TheFly
- 8 days ago - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer - GlobeNewsWire
- 13 days ago - Revolution Medicines initiated with an Overweight at Morgan Stanley - TheFly
- 14 days ago - Revolution Medicines price target raised to $230 from $215 at Stifel - TheFly
- 18 days ago - Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off. - Business Insider
- 20 days ago - NEJM publishes Phase 1/2 clinical data on daraxonrasib - TheFly